Investors still hold solid gains for the year so far, on average, as tech names flourish. Plus: A flashback to the 80th anniversary of the Bretton Woods monetary agreement.
(Bloomberg) -- Thomas Matthew Crooks, the 20-year-old gunman who shot and injured former President Donald Trump at a Pennsylvania rally, briefly appeared in an advertisement for BlackRock Inc., the company said on Sunday. Most Read from BloombergTrump Shooting Changes Biden’s Plan to Revive 2024 CampaignBlackRock Says Gunman From Trump Rally Appeared in Firm’s AdTrump Emerges Defiant From Rally Attack Set to Shake Up ’24 RaceI Was at the Trump Rally Where He Was Shot. Here Is What I SawGlobal Ma
Wall Street's next 10-for-1 stock split is being executed by a company whose business is, arguably, built on a house of cards.
If you ask investors about dividends, many would say, "the more, the merrier." Monthly dividends from REITs are popular because they allow shareholders to earn money effortlessly through direct deposits. Keep reading to find out how you can earn a ...
Preserve your mental capital by determining just how far you're willing to let a heavy-hitter like Nvidia stock run.
Dividend stocks have been under pressure lately as investors flocked to high-growth tech companies to ride the AI bandwagon. However, amid the latest data showing signs of easing inflation, many analysts believe possible rate cuts from the Federal ...
These fundamentally strong stocks can deliver exceptional returns for patient investors.
It's tempting to think of the Magnificent 7 as a group of stocks that moves in lockstep. That's not true, analysts say.
Yes, Nvidia is one of them. But it's not the only semiconductor game in town.
"Slowing GDP + accelerating EPS has been the best backdrop for stocks," Bank of America said in a note on Monday.
Pfizer (PFE) stock has been struggling, but looking among the market’s laggards can yield attractive opportunities. The stock is super cheap, sports a stellar 5.7% dividend yield and has an interesting potential catalyst on deck in the form of a new weight loss drug candidate that it is moving forward on developing. Plus, sell-side analysts believe the stock has potential upside of 17.1% over the next year. Significantly Cheaper Than the Overall Market So, how cheap is Pfizer? The stock trades a
